Stressors motivate an array of adaptive responses ranging from 'fight or flight' to an internal urgency signal facilitating long-term goals 1 . However, traumatic or chronic uncontrollable stress promotes the onset of major depressive disorder, in which acute stressors lose their motivational properties and are perceived as insurmountable impediments 2 . Consequently, stress-induced depression is a debilitating human condition characterized by an affective shift from engagement of the environment to withdrawal 3 . An emerging neurobiological substrate of depression and associated pathology is the nucleus accumbens, a region with the capacity to mediate a diverse range of stress responses by interfacing limbic, cognitive and motor circuitry 4 . Here we report that corticotropin-releasing factor (CRF), a neuropeptide released in response to acute stressors 5 and other arousing environmental stimuli 6 , acts in the nucleus accumbens of naive mice to increase dopamine release through coactivation of the receptors CRFR1 and CRFR2. Remarkably, severe-stress exposure completely abolished this effect without recovery for at least 90 days. This loss of CRF's capacity to regulate dopamine release in the nucleus accumbens is accompanied by a switch in the reaction to CRF from appetitive to aversive, indicating a diametric change in the emotional response to acute stressors. Thus, the current findings offer a biological substrate for the switch in affect which is central to stress-induced depressive disorders.
CRF initiates neuroendocrine signalling in the hypothalamicpituitary-adrenal axis and also regulates neurotransmission directly through two receptor subtypes, CRF receptor 1 (CRFR1) and CRFR2, which are distributed widely throughout the brain 7, 8 . In the nucleus accumbens, CRF facilitates cue-elicited motivation 9 and social bonding 10 , behaviours that are thought to be mediated by dopamine transmission 11, 12 . Therefore, we sought evidence for CRF-dopamine interactions in the nucleus accumbens, first using fluorescent immunohistochemistry. Dense CRF immunoreactivity was present throughout the rostro-caudal axis of the nucleus accumbens core and lateral shell, and in the most rostral portion of the medial shell in sparsely located large cell bodies (cholinergic interneurons, see Supplementary Fig. 1 ) and fibre terminals that were interdigitated with tyrosine-hydroxylase-immunoreactive fibres that are indicative of dopamine-containing axons ( Fig. 1a ). Immunoreactivity for the CRFR1 receptor displayed punctate staining with co-localization of tyrosine-hydroxylase immunoreactivity on fibre segments in addition to localization on cell bodies within the nucleus accumbens ( Fig. 1b and Supplementary Fig. 2 ). CRFR2 immunoreactivity had a more diffuse but still punctate pattern of staining, similar to that in other regions 13 , with some co-localization with tyrosine-hydroxylase immunoreactivity ( Fig. 1c and Supplementary Fig. 3 ). Expression of CRF receptors on subcellular profiles in the nucleus accumbens, including tyrosine-hydroxylase-positive terminals, was confirmed at higher spatial resolution using transmission electron microscopy ( Fig. 1d ; quantified in Supplementary Table 1 ). Together, these data indicate that the localization of CRF and its receptors in the nucleus accumbens is well-suited for modulation of dopamine release.
To directly test the functional effects of CRF on dopamine release in the nucleus accumbens, we selectively monitored dopamine release evoked by a single biphasic electrical pulse (2 ms per phase, 100-500 mA delivered once per minute) in acute coronal brain slices using fast-scan cyclic voltammetry at carbon-fibre microelectrodes ( Fig. 2a and Supplementary Fig. 4 ). Vehicle or CRF (10, 100 or 1,000 nM) was applied to the slice for 15 min after 5 min of stable baseline, and the resultant effect was quantified by averaging the evoked dopamine current in the last 10 minutes. After application of vehicle, there was a modest (,7%) decrease in dopamine release ( Fig. 2b) , whereas CRF increased dopamine release in a concentration-dependent manner eliciting effects significantly greater than vehicle at 100 and 1,000 nM (27.8 6 6.7 and 30.0 6 8.4%, respectively, mean 6 s.e.m.; F 3, 49 5 5.026, P , 0.01, one-way analysis of variance (ANOVA) with Dunnett's post-hoc t-tests; Fig. 2b and Supplementary Fig. 5 ). Interestingly, this effect could be blocked by application of either the selective CRFR1 antagonist, antalarmin (1 mM), or the selective CRFR2 antagonist, anti-sauvagine 30 (ASVG 30; 250 nM), to the slice beginning 20 min before CRF application (F 2, 50 5 5.142, P , 0.01, one-way ANOVA with Dunnett's post-hoc t-tests; Fig. 2c ) indicating that coactivation of both receptors is required. Consistently, CRF (10, 100, 1,000 nM) failed to increase dopamine release in the nucleus accumbens of mice with deletion of either the Crfr1 (ref. 14) or Crfr2 (ref. 15 ) gene ( Fig. 2d ). Application of the selective CRFR1 agonist stressin 1 (100 or 300 nM) or the selective CRFR2 agonist urocortin 3 (100 or 300 nM) failed to significantly increase dopamine release when applied individually (P . 0.05 compared to respective vehicles; Fig. 2e , f), but significantly increased dopamine release when applied together (F 3,36 5 3.528, P , 0.05 versus vehicle, one-way ANOVA with Dunnett's post-hoc t-tests). The effect of the agonists together could be blocked by pre-treatment with antalarmin and ASVG 30 (unpaired t-test, P . 0.05; Fig. 2g ). Together these data provide convergent evidence that CRF increases dopamine release in the nucleus accumbens through coactivation of CRFR1 and CRFR2. If this ability for CRF to positively regulate dopamine in the nucleus accumbens has specific motivational relevance to the behaving animal, we would predict that it would cause conditioned place preference when restricted to the nucleus accumbens, even though centrally administered CRF elicits robust conditioned place aversion 16 . Therefore, we used a balanced place-conditioning apparatus consisting of two visually distinct test chambers separated by a smaller neutral compartment. On day one, mice were allowed to freely roam the apparatus, and the time they spent in each chamber was recorded.
On days two and three, mice received CRF bilaterally into the nucleus accumbens (500 ng per side in 200 nl artificial cerebrospinal fluid; cannulae placements are shown in Supplementary Fig. 6 ) or vehicle infusions and were then isolated in one of the test chambers for 30 min. Four hours later they received the alternative infusion and were isolated in the other test chamber for 30 min. On day four, mice were again allowed free access to the apparatus. Following conditioning, mice exhibited a significant preference for the CRF-paired context, demonstrating that intra-accumbens CRF (500 ng) was an appetitive stimulus to these animals (conditioning by drug, F 1,12 5 6.435, P , 0.001, two-way repeated-measures ANOVA; Fig. 3a ). Similarly, unilateral infusions of CRF (500 ng in 200 nl) also produced conditioned place preference (conditioning by drug, F 1,12 5 11.77, P , 0.001 twoway repeated-measures ANOVA; Fig. 3b and Supplementary Fig. 7a ). This dose of CRF is within the range that produces selective effects in vivo 9 , but it is difficult to ascertain the steady-state concentration at receptors as CRF undergoes both radial diffusion and active clearance 17 . Nevertheless, even at a lower dose of CRF (5 ng in 200 nl), conditioned place preference was observed (conditioning by drug, F 1,14 5 5.415, P , 0.05, two-way repeated-measures ANOVA; Fig. 3b and Supplementary Fig. 7b ). Taken together, these data indicate that CRF acts in the nucleus accumbens to produce a positive affective state.
To test whether this positive affective state is dependent upon CRF's ability to increase dopamine release, we used the catecholaminergicneuron-selective neurotoxin, 6-hydroxydopamine (6-OHDA). We compared unilateral CRF place conditioning in animals that had received ipsilateral infusions of 6-OHDA (2 mg in 500 nl) versus vehicle (0.09% NaCl, 0.1% ascorbate) into the nucleus accumbens 7 days earlier. CRF (500 ng in 200 nl) produced place preference in sham animals (conditioning by drug, F 1,18 5 6.95, P , 0.05 two-way repeated-measures ANOVA; Supplementary Fig. 8a ), of similar magnitude to controls (treatment by drug, F 1,30 5 0.35, P . 0.05, two-way ANOVA). However, place preference to intra-accumbens CRF was absent in animals that received 6-OHDA (conditioning by drug, F 1,18 5 0.00, P . 0.05, two-way repeated-measures ANOVA; Supplementary Fig. 8b ) showing a significant change in the subjective effects of CRF (P , 0.05, unpaired t-test; Fig. 3b ). This 6-OHDA treatment produced a significant dopamine depletion on the side of the injection (P , 0.001; Supplementary Fig. 8c ), but did not alter locomotor activity (P . 0.05, unpaired t-test; Supplementary Fig. 8d ), demonstrating that the unilateral lesions did not produce a general deficit in motor function. These data demonstrate that the positive affective state produced by CRF in the nucleus accumbens is dependent on its ability to increase dopamine release.
To ascertain the role of endogenously released CRF in the nucleus accumbens in mediating appetitive behaviours, we tested the effect of CRF antagonism on the response to an arousing stimulus by assaying novel object exploration, a behaviour that requires intact dopamine transmission 18 . We bilaterally infused the CRF antagonist, a-helical CRF (500 ng in 200 nl per side) or vehicle (lactated ringer's with 1% acetic acid), into the nucleus accumbens, placed animals into an arena, and then 15 min later introduced a novel object into the centre. Although a-helical CRF had no effect on baseline exploration of the centre of the arena compared to vehicle, it significantly attenuated the appetitive effects (that is, eliciting of approach and exploration) of the novel object (treatment by stimulus, F 1,18 5 4.62, P , 0.05, two-way repeated-measures ANOVA; Fig. 3c ). These data demonstrate that endogenous CRF in the nucleus accumbens is used under physiological conditions to mediate appetitive responses to arousing environmental stimuli.
Exposure to severe or chronic stress can produce profound alterations in normal stress signalling that can be detrimental to physical and mental health, predisposing individuals to depression 19 . To model this phenomenon, we used a modified Porsolt paradigm in which mice are exposed to 2 days of repeated swim stress. Animals were placed in a vessel of water (29-31 uC) for 15 min followed by four additional LETTER RESEARCH 6-min swim sessions (separated by 6-min recovery periods) 24 h later. This protocol has been shown to produce escalating immobility across sessions, indicating a depression-like phenotype 20 . We prepared coronal slices of the nucleus accumbens from these animals 30 minutes after the final stress exposure and found that the ability for CRF to potentiate dopamine release was completely abolished (stress exposure by drug, F 4,116 5 12.61, P , 0.001 two-way ANOVA; Fig. 4a ). Notably, we established that this change in the ability of CRF to regulate dopamine release was not a generalized change in stress-related peptide signalling as the effect of a k-opioid agonist to reduce dopamine release was unaffected by the 2-day stress-exposure paradigm ( Supplementary  Fig. 9 ). Therefore, these data show that severe stress selectively abolishes CRF's ability to modulate dopamine release in the nucleus accumbens. Surprisingly, there was no recovery of the action of CRF on dopamine release in the nucleus accumbens 7, 30 or even 90 days after stress exposure (stress exposure by drug, F 4,116 5 4.852, P , 0.01, two-way ANOVA; Fig. 4a ). This time period is consistent with the protracted course of stress-induced depressive disorders 21 , and indeed, a depression-like phenotype was maintained across this 90-day post-stress period, as assessed by swim immobility (Supplementary Fig. 10 ). Importantly, the loss of the CRF response was not due to a baseline change in evoked dopamine release (Supplementary Fig. 11 ) and it was not simply an age-related phenomenon ( Supplementary Fig. 12 ). Therefore, we have shown that severe stress produces a persistent dysregulation of CRF-dopamine interactions that normally produce a positive affective state. Stress-induced depressive disorders are associated with altered levels of several neurochemicals that interact with the CRF system, including serotonin 22 , dynorphin 23 and glucocorticoids 4, 24 . Therefore, we targeted these systems to gain mechanistic insight into the stressinduced loss of CRF's regulation of dopamine release. We pretreated animals (10 ml kg 21 intraperitoneal) with vehicle, fluoxetine (selective serotonin-reuptake inhibitor; 10 mg kg 21 ), norBNI (k-opioid-receptor antagonist; 10 mg kg 21 ) or RU486 (glucocorticoid-receptor antagonist; 30 mg kg 21 ) before stress exposure on each of the swim-stress days. The animals were allowed to recover for 7 days, then slices were prepared and the CRF response was tested. Although acute regimens of fluoxetine do not alleviate pre-existing depression-related symptoms in patients or animal models, they have been shown to prevent the induction of some depression-like responses to stress 25 . Nevertheless, this treatment did not affect the abolition of CRF modulation of dopamine release by stress (P . 0.05; Supplementary Fig. 13 ). Similarly, this stress-induced perturbation was not significantly affected by norBNI (P . 0.05; Supplementary Fig. 13 ); however, it was prevented by RU486 (30 mg kg 21 ; P , 0.001; Fig. 4a and Supplementary Fig. 13 ), even at a lower dose (10 mg kg 21 ; P , 0.01; Supplementary Fig. 13 ). These data show that glucocorticoid signalling is a critical component of the profound stress-induced dysregulation of CRF-dopamine interactions in the nucleus accumbens.
This robust loss of the neurochemical response to CRF in the nucleus accumbens after severe stress suggests a long-lasting alteration in its subjective qualities. To test this idea, we used the placeconditioning paradigm in animals that had been exposed to the 2-day swim-stress regimen. Mice that underwent repeated swim stress 7 days before conditioning spent significantly less time in the CRFpaired chamber than in the vehicle-paired chamber after conditioning, establishing that CRF in the nucleus accumbens is now aversive to these animals (conditioning by drug, F 1, 10 5 5.824, P , 0.01, twoway ANOVA, Supplementary Fig. 14a ). Therefore, severe stress produces a diametric shift in the subjective qualities of CRF in the nucleus accumbens from positive to negative (Fig. 4b) . Consistent with the enduring loss of CRF regulation of dopamine observed in vitro, the 
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absence of CRF conditioned place preference persisted for at least 90 days after repeated stress exposure (F 2,20 5 6.870, P , 0.05, oneway ANOVA with Dunnett's post hoc; Fig. 4b and Supplementary  Fig. 14b ). Similarly, endogenously released CRF no longer stimulated exploration of a novel object when tested 7 days after stress exposure (stimulus by drug, F 1,16 5 0.004, P . 0.05, two-way repeated-measures ANOVA; Supplementary Fig. 15 ) showing that severe stress abolished the function of CRF in the nucleus accumbens to stimulate appetitive responses to arousing stimuli (unpaired t-test, P , 0.05, Fig. 4c ). Therefore, these findings demonstrate the long-term loss of a regulatory mechanism of motivated behaviour after severe stress.
Major depressive disorder has a lifetime prevalence of 17%, making it one the world's greatest public-health concerns 26 ; however, its molecular foundation has been elusive. Patients suffering from this disorder present with constellations of symptoms that include loss of affect, cognitive impairment and homeostatic imbalance 27 ; symptoms that are presumably precipitated by dysregulation of several brain regions 4 . It is established that glucocorticoid-dependent hippocampal atrophy is a critical mediator of cognitive impairment in depression such as memory loss 4 . More recently, disruption of nucleus accumbens function has been implicated in the affective symptoms of depression 4 . In the current work, we studied the actions of CRF on neurotransmission within this brain region in an attempt to connect pathological stress-related neuroadaptation with the shift in affect observed in depressed patients.
CRF receptors are distributed widely throughout the brain 8 and mediate disparate effects (see Supplementary Discussion) . Our data highlight the specificity of the local action of both exogenously applied and endogenously released CRF in the nucleus accumbens in producing a positive, rather than negative, subjective state by increasing dopamine release. Importantly, we show that severe stress disables this capacity of CRF to positively regulate dopamine, removing CRF's appetitive qualities, leaving a negative perceptual bias. This dysregulation is mediated by glucocorticoid, but not k-opioid, receptors and is not ameliorated by acute prophylactic administration of a selective serotonin-reuptake inhibitor. Glucocorticoid signalling has been shown to have genomic repressive effects on the CRF system, in particular the downregulation of CRFR1 24 . Genetic deletion of the CRFR1 gene selectively from dopamine neurons increases anxiety-like behaviour 28 , demonstrating further that disruption of CRF-dopamine interactions alone is sufficient to produce a negative affective state similar to that following severe stress 29 .
Collectively, our data show a specific defect in the regulation of dopamine transmission in the nucleus accumbens as a consequence of exposure to stress that induces depression-like behaviour. Depressive disorders produce a profound change in the perception of, and behavioural response to, acute stressors and other arousing environmental stimuli that elicit CRF signalling. Taken together, our findings provide a neurobiological mechanism for the affective shift from engagement of the environment to withdrawal following severe stress, central to the manifestation of major depressive disorder.
METHODS SUMMARY
Subjects. Male C57BL/6 mice aged .50 days had ad libitum access to food and water. Mice housed together (two to four per cage) were subjected to the same behavioural treatments. All animal procedures were approved by the University of Washington Institutional Animal Care and Use Committee. Neuroanatomy. Immunohistochemistry was carried out as described previously 20 . Sections were incubated for 24 h with a mixture of mouse anti-tyrosine hydroxylase 1:1,000 and rabbit anti-CRF (peptide) 1:150, and chicken anti-ChAT antibody 1:150 or rabbit anti-CRFR1 or goat anti-CRFR2 (1:100 to 1:500), then incubated in the appropriate fluorescently tagged secondary antibodies (1:500), and were imaged using epifluorescent and confocal microscopes. Transmission electron microscopy was carried out as previously described 30 .
Fast-scan cyclic voltammetry. 250-mm coronal slices containing the nucleus accumbens were continuously perfused (1.5-2.0 ml min 21 ) with oxygenated artifical cerebrospinal fluid (aCSF) maintained at 31-33 uC. The potential at a carbon-fibre electrode was held at 20.4 V versus Ag/AgCl, ramped to 11.3 V and back to 20.4 V (400 V s 21 ) every 100 ms. A single biphasic electrical pulse (2 ms per phase, 100-500 mA) was applied to the slice to evoke dopamine release. Conditioned place preference. A three-compartment place-conditioning apparatus was used to measure preference as described previously 20 . On days 2 and 3, mice received two intra-accumbens microinjections per day: one injection of aCSF and one injection of CRF (500 ng in 200 nl per side) paired with different chambers. On day 4, mice were allowed free access to the apparatus for 30 min. At the end of behavioural testing, cannulae placements were assessed. Novel-object exploration. The novel object exploration assay was similar to an assay that has been described previously 28 . Animals received bilateral intra-accumbens microinfusions of vehicle or a-helical CRF (500 ng in 200 nl) counterbalanced across 2 days of testing. On each testing day, the animal was exposed to a new novel object. , and in animals that were pretreated with the glucocorticoidreceptor antagonist, RU486 (30 mg kg 21 , intraperitoneal) or its vehicle before stress (right panel; n 5 6-10). b, Mean place preferences for intra-accumbens CRF in naive (blue) and stress-exposed mice (red) (left panel; n 5 6-8) and representative activity traces (right). c, Difference in the increased centre time during presentation of a novel object between vehicle and CRF-receptor antagonism in naive (blue) animals and in animals 7 days post stress (red) (n 5 9-10). Error bars, s.e.m. NS, P . 0.05, *P , 0.05, **P , 0.01; 1P , 0.05; 11P , 0.01 for interaction.
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